Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)
Atea Pharmaceuticals (AVIR) posted quarterly Current Deferred Revenue of $192.2 million for Q3 2021, down 14.58% quarter-over-quarter from $225.0 million in Q2 2021.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Atea Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $192.2 million for Q3 2021.
- In Q3 2021, Current Deferred Revenue changed N/A year-over-year to $192.2 million; the TTM figure through Sep 2021 stood at $192.2 million (changed N/A YoY), while the FY2020 annual figure was $301.4 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2021 stood at $192.2 million, down from $225.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $301.4 million in Q4 2020, with the low at $192.2 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 192.18 Mn |
| Jun 30, 2021 | 224.99 Mn |
| Mar 31, 2021 | 235.38 Mn |
| Dec 31, 2020 | 301.37 Mn |